BURJEEL HOLDINGS PLC

Axiom Space and Burjeel Holdings have signed a Memorandum of Understanding to conduct scientific research and test new technologies in space, focusing on how the human body reacts in microgravity. The collaboration aims to expand access to microgravity for medical advancements. The announcement was made at a signing ceremony in New York, attended by key executives from both organizations. As their first initiative, they plan to send a suite of medical capabilities to space, which will be used by Axiom Space astronauts during their training and the upcoming Axiom Mission 4 (Ax-4). This research will study the effects of microgravity on biomarkers, drug substance quality, and remote health services. The partnership is intended to benefit medical innovation and patient outcomes globally, aligning with the UAE's vision for space exploration.

Burjeel Holdings PLC, a leading healthcare provider in the MENA region, has announced plans to expand its women and children healthcare services by launching IVF services. This expansion will be integrated into their existing comprehensive portfolio, which includes advanced gynecology, fetal medicine, and pediatric subspecialties. The Trust Fertility Clinic, part of Burjeel Medical City, will be the largest fertility center in the UAE, offering advanced personalized fertility care and cutting-edge technologies such as AI-driven embryo selection. The clinic will be led by Dr. Walid Sayed, an expert in reproductive endocrinology and infertility. This initiative aims to provide a seamless journey for women from conception to delivery, ensuring high standards of care for both maternal and newborn health. The expansion reflects Burjeel's commitment to meeting the growing demand for fertility services in the region and providing world-class, personalized care.

Abu Dhabi Stem Cells Center (ADSCC) and Burjeel Holdings PLC have formed a strategic partnership to expand bone marrow transplant and cellular therapy services at Burjeel Medical City (BMC). This collaboration aims to enhance access to advanced care for patients with blood cancer, genetic diseases, autoimmune diseases, and other conditions, establishing Abu Dhabi as a global healthcare destination. ADSCC will extend its proprietary Abu Dhabi Bone Marrow Transplant Program (AD-BMT©) to BMC, which is accredited by the Department of Health - Abu Dhabi and recognized by the Foundation for the Accreditation of Cellular Therapy (FACT). ADSCC has achieved significant milestones in bone marrow transplantation and CAR-T Cell Therapy since 2020. The Burjeel Cancer Institute (BCI) at BMC has also pioneered bone marrow transplants, including the UAE’s first pediatric BMT in 2022. The partnership aims to create an integrated ecosystem for advanced research, cellular therapy, and regenerative medicine, benefiting new and existing patients. Both institutions are committed to setting new benchmarks in patient outcomes and medical excellence.

Burjeel Holdings PLC, a leading healthcare services provider in the MENA region listed on the Abu Dhabi Securities Exchange, has been included in the FTSE Global Equity Index Series - Middle East & Africa following the latest semi-annual review. The changes will be effective after market close on September 20, 2024, and will be reflected from September 23, 2024. Burjeel's inclusion in several FTSE indices highlights its importance in the UAE capital markets and is expected to enhance investor confidence and visibility among global institutional investors. The FTSE Global Equity Index Series includes over 19,000 securities across 49 markets globally. Founded in 2007, Burjeel operates 89 assets across the UAE, Oman, and Saudi Arabia, including hospitals, medical centers, pharmacies, and other services.

Burjeel Holdings PLC, a leading healthcare services provider in MENA, has received a provisional "AAA" ESG rating from MSCI, placing it among the top 6% of global healthcare leaders in environmental, social, and governance performance. This rating highlights Burjeel’s effective management of ESG-related risks and opportunities, including reducing environmental impact, ensuring safety and quality in healthcare services, strong labor management, and robust privacy and data protection measures. The recognition aligns with the UAE's vision for sustainable socioeconomic development. Burjeel's new long-term ESG strategy focuses on promoting well-being, sustainability, and carbon neutrality by 2040. The Group has already achieved significant milestones, including awards for diversity, inclusion, and sustainable practices.

Burjeel Holdings PLC, a leading super-specialty healthcare services provider in the MENA region listed on the Abu Dhabi Securities Exchange, reported double-digit revenue growth for the first half of 2024. The Group's revenue increased by 10% to AED 2.4 billion, driven by a 6% rise in patient footfall and improvements in patient yield. Burjeel Medical Center (BMC) saw a 21% growth in top-line revenue, with patient footfall reaching 3.1 million in H1'24 and accelerating to 11% in Q2'24. BMC's EBITDA rose by 41% to AED 93 million, while the hospitals' EBITDA grew by 9% to AED 464 million, reflecting strong growth in oncology and other advanced specialty services. The hospitals' net profit improved by 24% to AED 253 million due to growth asset ramp-up and cost optimization. Burjeel Holdings also launched IMed Technologies to create AI-based health tech solutions, aiming to enhance patient care, provider satisfaction, and financial performance.